<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679482</url>
  </required_header>
  <id_info>
    <org_study_id>FONCI6001</org_study_id>
    <nct_id>NCT02679482</nct_id>
  </id_info>
  <brief_title>Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma</brief_title>
  <acronym>FPSPLTTCOAG</acronym>
  <official_title>Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Oftalmológica Nacional</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Oftalmológica Nacional</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to follow and describe the outcomes of patients after selective
      and pascal laser trabeculoplasty treatment for chronic open-angle glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selective laser trabeculoplasty (SLT) and pattern laser trabeculoplasty (PLT, a novel
      computer-guided laser that is being using to treat open-angle glaucoma) are two laser surgery
      methods to make a trabeculoplasty on patients with open angle glaucoma. An observational
      prospective study will be performed, a consecutive convenience sample patients with
      indication for SLT or PLT will be recruited during June 2014 to uly 2016 and follow-up until
      6 months, at the Fundación Oftalmológica Nacional (Bogotá-Colombia). A non-probabilistic
      convenience sampling is performed, considering that the average number of patients diagnosed
      with chronic open-angle glaucoma undergoing to Laser trabeculoplasty at the Oftalmológica
      Nacional Fundacion corresponds to approximate 2 per month. Therefore it is expected to enroll
      one patient per month for each of the laser used (SLT and PLT) for trabeculoplasty. Finally
      obtaining a sample size of 18 patients per type of laser for a total of 36 patients in the
      recruitment period, between September 2014 and July 2016.

      This study is strictly observational, that's why the laser procedure is covered by the
      national health insurance of each patient, as well the complications due to the same
      procedure. An evaluation pre trabeculoplasty and a consecutive 5 visits will be perform as
      follows:

      Visit 0 - Pre-procedure visit: the subjects that will undergo laser trabeculoplasty either
      Selective laser or PASCAL laser will be invited to participate and an informed consent will
      be carried out. The information concerting to demographics characteristics (study eye, age,
      gender and ethnicity), clinical characteristics (date of glaucoma diagnosis, number of
      medications used to treat glaucoma, time of use of actually anti-glaucomatous topical
      medication) and slit lamp and ophthalmoscopy examination (corneal aspect, iris color, pupil
      gonioscopy, intraocular pressure, lens status, vitreous cells, vertical C/D ratio, optic
      nerve edge, rim characteristic [ISNT pattern], peripapilar atrophy, state of fovea, state of
      peripheral retina and state of choroid for both eyes) will be extracted and recorded on
      respective case report form (CRF). The data will be scored according to the grading criteria
      outlined below:

      Study eye: the eye under the follow-up 0 - Right eye 1 - Left eye

      Geder: the state of being male or female 0 - Male 1 - Female

      Ethnicity: the fact or state of belonging to a social group that has a common national or
      cultural tradition.

      0 - Hispanic

        1. - Black

        2. - White

        3. - Asian

      Number of medications used: anti-glaucoma medication used by the patient 0 - 0

        1. - 1

        2. - 2

        3. - 3

        4. - 4

      Corneal aspect: state in which the cornea is at baseline 0 - Normal 1 - Anormal

      Iris color: iris pigmentation 0 - Light

        1. - Medium

        2. - Dark

      Gonioscopy (Shaffer classification): amplitude of irido-corneal angle maseure by poster lens
      and noted by the Shaffer scale on each quadrant superior, nasal, temporal and inferor angle 0
      - 0

        1. - 1

        2. - 2

        3. - 3

        4. - 4

      Intraocular pressure: pressure inside the eye measured in millimeters of mercury Value in
      mmhg, measure with Goldman tonometer

      Lens status: clouding of the lens Nuclear, Subcapsular and Cortical 0 - 0

        1. - 1

        2. - 2

        3. - 3

        4. - 4

      Vitreous cells: number of cells per milimeter in the vitreous cavity 0 - 0 1 - traces 2 - +1
      3 - +2 4 - +3 5 - +4

      Vertical C/D ratio: relation between cup and optic nerve disc 0 - 0.1

        1. - 0.2

        2. - 0.3

        3. - 0.4

        4. - 0.5

        5. - 0.6

        6. - 0.7

        7. - 0.8

        8. - 0.9

        9. - 1.0

      Optic nerve edge: regularly over the optic disc 0 - Regular

      1 - Irregular

      Rim characteristic [ISNT pattern]: reduction pattern in the thickness of neural ring 0 -
      Conserved 1 - Not conserved

      Peripapilar atrophy: presence of atrophy over the disc 0 - Alfa

      1 - Beta 3 - Not apply

      State of fovea: normality of the fovea 0 - normal

      1 - abnormal

      State of peripheral retina: state of the peripheral retina 0 - normal

      1 - abnormal

      State of choroid: choroidal health 0 - normal

      1 - abnormal

      After the visit 0, a 5 consecutive visits will be performed: for 1 day, 1 week, 1 month, 3
      months and 6 months after the procedure. Identical data will be extracted, ophthalmological
      examination data, slit lamp exam, and the computerized visual fields (CVF) (CVF only at 3 and
      6 months).

      One member of the investigation team will collect all information during the follow-up time,
      and a second one member will review and collate data.

      Statistical analysis will be performed in SPSS version 21. Univariate analyzes will perform;
      for categorical variables, frequency distribution will be made and reported in percentage,
      for the quantitative variables a measure of central tendency and dispersion will be made
      (mean, standard deviation and range) will calculate according to the relevance for each
      variable analyzed. Demographics such as age and gender variables will be described. For
      bivariate analysis comparing polytomous qualitative and quantitative variables (evolution of
      intraocular pressure with the type of trabeculoplasty used, number of antihypertensive
      medications required after the procedure with the type of trabeculoplasty, quantification of
      cellularity in the anterior chamber with type of trabeculoplasty) using parametric
      statistical analysis with ANOVA for independent samples and nonparametric with Kruskal-Wallis
      test. Also comparison of quantitative variables with quantitative variables (intraocular
      pressure before treatment and evolution of intraocular pressure after treatment) will be
      performed using the parametric inferential statistical Pearson correlation analysis and for
      nonparametric a Spearman correlation will be made. Finally, compare qualitative variables
      with qualitative variables (presence of peak intraocular pressure with type of laser
      trabeculoplasty performed) using the non-parametric statistical analysis Chi square test,
      Fisher exact test and Mac Nemar will make.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Six months</time_frame>
    <description>The eye pressure measured in millimeters of mercury, measure with Goldman tonometer at follow-up period</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma, Primary Open Angle</condition>
  <condition>Exfoliation Glaucoma</condition>
  <condition>Glaucoma, Pigmentary</condition>
  <arm_group>
    <arm_group_label>Selective laser trabeculoplasty (SLT)</arm_group_label>
    <description>Patients who underwent to Selective laser trabeculoplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pattern laser trabeculoplasty (PLT)</arm_group_label>
    <description>Patients who underwent to Pattern laser trabeculoplasty</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Open-Angle Glaucoma with a non-optimal intraocular pressure control
        with topical/oral medications, who underwent to laser trabeculoplasty treatment, attending
        the Fundacion Oftalmológica Nacional between June 2014 and july 2016 on Bogotá-Colombia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either sex, aged ≥ 40 years

          -  Best distant visual acuity, better than or equal to 20/200

          -  Diagnosis of primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary
             glaucoma, with open angles by Posner lens gonioscopy

          -  Intraocular pressure ≥ 20 mmHg, with medical treatment, as monotherapy or combination
             therapy.

          -  Previous computerized visual field within the six months previous performing
             trabeculoplasty

          -  Patients who understand and sign the informed consent

          -  Patient diagnosed with open-angle glaucoma who will undergo selective laser
             trabeculoplasty (SLT) with an amplitud of 360 degrees, or laser trabeculaplastia in
             pattern (PASCAL-Pattern Scan Laser) with an amplitud of 360 degrees. Made at initial
             session or in two 7 days separate sessions (each with session with an amplitude of180
             degrees)

        Exclusion Criteria:

          -  Advanced loss on visual field within 10 degrees of central fixation in a previous 3
             months visual field

          -  Previous history of surgery for glaucoma management, except peripheral iridotomy

          -  Corneal disease that does not allow the use of applanation tonometer nor an accurate
             measurement of intraocular pressure

          -  Corneal disease which prevents adequate visualization of trabeculo by gonioscopy lens

          -  Use of topical or systemic steroids

          -  Concomitant participation in another study

          -  Coexistence of other ocular pathology different than cataract.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Belalcazar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Oftalmológica Nacional</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Carvajal</last_name>
    <phone>+57-311-856-4991</phone>
    <email>crcarvajal@fon.org.co</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriana Cerquera</last_name>
    <phone>+57-310-383-5075</phone>
    <email>acerquera@fon.org.co</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundacion Oftalmológica Nacional</name>
      <address>
        <city>Bogota</city>
        <zip>110231</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandra Belalcazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hector D Forero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaira Zambrano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24367649</url>
    <description>Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/575877</url>
    <description>Argon laser therapy for open-angle glaucoma. A pilot study</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/18029271</url>
    <description>Selective laser trabeculoplasty</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/7789416</url>
    <description>Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/18586905</url>
    <description>Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24381726</url>
    <description>Glaucoma management: relative value and place in therapy of available drug treatments</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/16883356</url>
    <description>Economics of selective laser trabeculoplasty as primary therapy for glaucoma</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21453963</url>
    <description>Glaucoma</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21849211</url>
    <description>Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/5078295</url>
    <description>Laser puncture of the anterior chamber angle in glaucoma (a preliminary report)</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/6493712</url>
    <description>Argon laser trabeculoplasty. Studies of mechanism of action</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/16234461</url>
    <description>A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/10670472</url>
    <description>Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalph</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/2255512</url>
    <description>Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/3355425</url>
    <description>Trabecular cell division after argon laser trabeculoplasty</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19026324</url>
    <description>Argon laser trabeculoplasty versus selective laser trabeculoplasty</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/16199969</url>
    <description>Argon versus selective laser trabeculoplasty in the treatment of open angle glaucom</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23769780</url>
    <description>Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma</description>
  </link>
  <reference>
    <citation>Wang W, He M, Zhou M, Zhang X. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. PLoS One. 2013 Dec 19;8(12):e84270. doi: 10.1371/journal.pone.0084270. eCollection 2013. Review.</citation>
    <PMID>24367649</PMID>
  </reference>
  <reference>
    <citation>Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979 Feb;97(2):319-22.</citation>
    <PMID>575877</PMID>
  </reference>
  <reference>
    <citation>Barkana Y, Belkin M. Selective laser trabeculoplasty. Surv Ophthalmol. 2007 Nov-Dec;52(6):634-54. Review.</citation>
    <PMID>18029271</PMID>
  </reference>
  <reference>
    <citation>Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995 Apr;60(4):359-71.</citation>
    <PMID>7789416</PMID>
  </reference>
  <reference>
    <citation>Sanghvi C, McLauchlan R, Delgado C, Young L, Charles SJ, Marcellino G, Stanga PE. Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol. 2008 Aug;92(8):1061-4. doi: 10.1136/bjo.2008.139568. Epub 2008 Jun 27.</citation>
    <PMID>18586905</PMID>
  </reference>
  <reference>
    <citation>Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014 Jan;5(1):30-43. doi: 10.1177/2040622313511286. Review.</citation>
    <PMID>24381726</PMID>
  </reference>
  <reference>
    <citation>Buys YM. Economics of selective laser trabeculoplasty as primary therapy for glaucoma. Can J Ophthalmol. 2006 Aug;41(4):419-20.</citation>
    <PMID>16883356</PMID>
  </reference>
  <reference>
    <citation>Quigley HA. Glaucoma. Lancet. 2011 Apr 16;377(9774):1367-77. doi: 10.1016/S0140-6736(10)61423-7. Epub 2011 Mar 30. Review.</citation>
    <PMID>21453963</PMID>
  </reference>
  <reference>
    <citation>Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, Smith SD. Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology. 2011 Nov;118(11):2296-302. doi: 10.1016/j.ophtha.2011.04.037. Epub 2011 Aug 17.</citation>
    <PMID>21849211</PMID>
  </reference>
  <reference>
    <citation>Krasnov MM. [Laser puncture of the anterior chamber angle in glaucoma (a preliminary report)]. Vestn Oftalmol. 1972;3:27-31. Russian.</citation>
    <PMID>5078295</PMID>
  </reference>
  <reference>
    <citation>Van Buskirk EM, Pond V, Rosenquist RC, Acott TS. Argon laser trabeculoplasty. Studies of mechanism of action. Ophthalmology. 1984 Sep;91(9):1005-10.</citation>
    <PMID>6493712</PMID>
  </reference>
  <reference>
    <citation>Alvarado JA, Alvarado RG, Yeh RF, Franse-Carman L, Marcellino GR, Brownstein MJ. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005 Nov;89(11):1500-5.</citation>
    <PMID>16234461</PMID>
  </reference>
  <reference>
    <citation>Bradley JM, Anderssohn AM, Colvis CM, Parshley DE, Zhu XH, Ruddat MS, Samples JR, Acott TS. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci. 2000 Feb;41(2):422-30.</citation>
    <PMID>10670472</PMID>
  </reference>
  <reference>
    <citation>The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology. 1990 Nov;97(11):1403-13.</citation>
    <PMID>2255512</PMID>
  </reference>
  <reference>
    <citation>Bylsma SS, Samples JR, Acott TS, Van Buskirk EM. Trabecular cell division after argon laser trabeculoplasty. Arch Ophthalmol. 1988 Apr;106(4):544-7.</citation>
    <PMID>3355425</PMID>
  </reference>
  <reference>
    <citation>Pham H, Mansberger S, Brandt JD, Damji K, Ramulu PY, Parrish RK. Argon laser trabeculoplasty versus selective laser trabeculoplasty. Surv Ophthalmol. 2008 Nov-Dec;53(6):641-6. doi: 10.1016/j.survophthal.2008.08.020.</citation>
    <PMID>19026324</PMID>
  </reference>
  <reference>
    <citation>Zhao JC, Grosskreutz CL, Pasquale LR. Argon versus selective laser trabeculoplasty in the treatment of open angle glaucoma. Int Ophthalmol Clin. 2005 Fall;45(4):97-106. Review.</citation>
    <PMID>16199969</PMID>
  </reference>
  <reference>
    <citation>Wang H, Cheng JW, Wei RL, Cai JP, Li Y, Ma XY. Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma. Can J Ophthalmol. 2013 Jun;48(3):186-92. doi: 10.1016/j.jcjo.2013.01.001. Review.</citation>
    <PMID>23769780</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2016</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>February 13, 2016</last_update_submitted>
  <last_update_submitted_qc>February 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Open Angle Glaucoma</keyword>
  <keyword>Selective Laser Trabeculoplasty</keyword>
  <keyword>Pattern Scan Laser Trabeculoplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

